Ariad Pharmaceuticals Inc fka ARIA

[JJM760]

From my perspective, the shareholders have been taking a "temporary hit" for more than 20 years now. The market cap is over $3 billion because of the enormous amount of shares outstanding. I think from the markets perspective you now move from being a small time R&D biotech to a drug company by getting big boy financing like the rest of the world does. We all pay for the cost of capital in business. I think it's time to stop diluting the shareholders. If Ponatinib is the Superdrug that Ariad feels it is, this interest will be a nonevent in 5 years.

That's my two cents.